The findings of this study performed in vitro and in vivo support the presence of a new adaptive mechanism that may offer additional strategies to treat NAFLD by regulating the HIF-1α-LIPIN 1 pathway that need to be confirmed by additional studies. The gene discussed is LPIN1; the disease is metabolic dysfunction-associated steatotic liver disease.